about
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.The response of autologous T cells to a human melanoma is dominated by mutated neoantigensAdoptive T cell therapy for cancer in the clinicUpdate on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.Safety of targeting tumor endothelial cell antigensNovel technologies and emerging biomarkers for personalized cancer immunotherapySystems Biology Approach for Cancer Vaccine Development and EvaluationNanoengineering approaches to the design of artificial antigen-presenting cellsT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell linesEmerging clinical applications of RNASurvivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignanciesIn silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancerCancer immunotherapy via dendritic cellsPhosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivoProtein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.Clinical applications of a peptide-based vaccine for glioblastoma.Immunotherapy in acute leukemiaEGFRvIII-targeted vaccination therapy of malignant glioma.DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits.Immunity to stemness genes in human cancer.RNA-transfected dendritic cells in cancer immunotherapy.T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth.HSPPC-96: a personalised cancer vaccine.Neoantigens in cancer immunotherapy.Trial Watch: Peptide-based anticancer vaccines.Translating tumor antigens into cancer vaccinesCancer genetics and tumor antigens: time for a combined view?Telomerase as a universal tumor-associated antigen for cancer immunotherapy.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Regulation of tumour immunity by CD25+ T cells.Immunological weapons against acute myeloid leukaemia.Telomerase as a tumor-associated antigen for cancer immunotherapyAdjuvant therapy for high-risk primary and resected metastatic melanoma.RNA-transfected dendritic cells.ALK a novel lymphoma-associated tumor antigen for vaccination strategies.
P2860
Q24531314-3FF18517-7606-4551-9FD3-DEE9C8C39D83Q24535034-243A0212-F26C-4C22-B92F-BAD582454243Q24680405-3AF1938B-81F5-44B9-89DA-16D734496D03Q24801995-0DDCE9B6-7975-4CE9-867B-163ECA48510BQ24814838-02F7B541-D58E-41F7-84A1-6CDDC1042EB6Q26748863-79940403-A1F9-47B1-BF50-6D7201FA6E0DQ26770780-6A2BB537-F7F8-4885-B0CF-52505F538BF6Q26782580-6E1E3563-76EA-48A7-8A49-B9979F783CA5Q27023634-502643A5-EC32-417B-8C40-85CEA6F8814CQ27335110-D755C858-459C-4F1D-8418-85C9B7F5253EQ28208569-B4CBAE34-766B-49E5-81B4-3019B9E16895Q28214164-B417DCC1-D546-4938-B6B7-BDBABA034B10Q28251858-D7DFBEAD-0D85-4343-8567-752F207D7988Q28303131-5AC17D46-B260-466E-B0B0-BF4B931A7D7BQ29615444-E03AC010-13BE-4A92-8B3A-DFC609779912Q30306583-FA027891-EAE3-47ED-9744-BFA74DD673A1Q33384384-1081F57D-A9D0-440F-AC34-3D96BF6EAD53Q33421740-EB020C90-525D-40AE-9DE2-71F4298EB3A4Q33668575-B4F940D9-69C4-4CE2-943B-B8155FD85401Q33731552-8BA39453-FADE-46AD-B6BA-96C98D086F75Q33758459-9B772994-393E-4479-99BD-12481980CD48Q33811834-F823562B-70FA-4F0D-934E-8DF0CA7AC3BDQ33943241-13E2C82D-F3B2-4E7D-9DC3-FD36C2CF6A65Q34078072-FF33D796-30E4-4A3C-AD84-E34CFF4FA23FQ34191186-EC916B56-DB7B-4B54-A403-9FF8D2BF8015Q34265381-5DCFAB6C-C0EC-4EA8-93BD-57EAB405F67AQ34302985-2F626755-87FB-414E-8A54-85F39C5BB480Q34452027-68215C46-0CF0-43F0-9312-2C632D136053Q34470074-92CE9C21-B885-4D07-BA13-A164DE151639Q34483345-5CA4FEE2-086F-4842-A5F3-044DEAED53F6Q34484042-4444151E-448E-4B77-9463-F43FDBF28306Q34495646-87C5AEC6-F751-4B29-8532-0B47BA7D4503Q34535727-A193DC6B-0585-4B63-825D-CD0C5EF54E00Q34669820-2CD84D78-4DFF-442B-9AAD-5DE758391D8AQ34842135-5985E079-4A40-4005-ADBE-F0BB68E56374Q34842175-25C56AFF-CA13-4D98-B45D-2F385B4EA73BQ34878113-B07316D7-319B-4370-9305-0ECD1FB54DDFQ35048323-F57A3EB6-2117-4AA2-AD04-DEAFB66A0DDEQ35193518-01F926D0-4675-4CCF-9678-E96747D45ED1Q35614635-AE29004C-DCFC-4906-B2E7-365278FB3009
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The makings of a tumor rejection antigen.
@ast
The makings of a tumor rejection antigen.
@en
type
label
The makings of a tumor rejection antigen.
@ast
The makings of a tumor rejection antigen.
@en
prefLabel
The makings of a tumor rejection antigen.
@ast
The makings of a tumor rejection antigen.
@en
P1433
P1476
The makings of a tumor rejection antigen.
@en
P2093
P304
P356
10.1016/S1074-7613(00)80101-6
P407
P577
1999-09-01T00:00:00Z